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Using microarray analysis, we identified a unique ras
superfamily gene, termed RERG (ras-related and estro-
gen-regulated growth inhibitor), whose expression was
decreased or lost in a significant percentage of primary
human breast tumors that show a poor clinical progno-
sis. Importantly, high RERG expression correlated with
expression of a set of genes that define a breast tumor
subtype that is estrogen receptor-positive and associ-
ated with a slow rate of tumor cell proliferation and a
favorable prognosis for these cancer patients. RERG
mRNA expression was induced rapidly in MCF-7 cells
stimulated by -estradiol and repressed by tamoxifen
treatment. Like Ras, RERG protein exhibited intrinsic
GDP/GTP binding and GTP hydrolysis activity. Unlike
Ras proteins, RERG lacks a known recognition signal
for COOH-terminal prenylation and was localized pri-
marily in the cytoplasm. Expression of RERG protein in
MCF-7 breast carcinoma cells resulted in a significant
inhibition of both anchorage-dependent and anchorage-
independent growth in vitro and inhibited tumor forma-
tion in nude mice. These features of RERG are strikingly
different from most Ras superfamily GTP-binding pro-
teins and suggest that the loss of RERG expression may
contribute to breast tumorigenesis.
Microarray analysis of primary human tumors has led to the
identification of novel tumors subtypes that were not identified
previously and to the discovery of new genes that may be
involved in the disease process. When using hierarchical clus-
tering to classify breast tumors based upon variations in gene
expression patterns, 4–5 distinct breast tumor subtypes were
identified (1, 2). In addition, it has been shown that these
tumor subtypes were predictive of disease outcome (2); in the
extended study of Sørlie et al. (2), the breast tumor data was
statistically analyzed to identify genes whose expression pat-
terns correlated with overall patient survival (2). In the present
study, we focus on one of the genes whose high expression
correlated with a favorable patient outcome and whose expres-
sion pattern helped to define a breast tumor subtype that also
expressed the estrogen receptor (ER).1 This gene encodes a
novel member of the Ras superfamily of small GTPases that we
have designated RERG.
The mammalian Ras superfamily members serve as molec-
ular switches to regulate a diverse array of cellular functions.
These include control of cellular proliferation, differentiation,
regulation of the actin cytoskeleton, membrane trafficking, and
nuclear transport (3–6). Despite sequence differences between
subfamily members, all Ras-related GTPases contain five
highly conserved domains (G1-G5) and function as guanine
nucleotide-dependent molecular switches. For example, the
prototypic Ras proteins transduce signals for growth and differen-
tiation by alternating between active guanosine triphosphate
(GTP)-bound and inactive guanosine diphosphate (GDP)-bound
conformational states (7). When in their active GTP-bound state,
Ras-related proteins interact through their effector domain with a
variety of cellular targets to elicit their biological effects.
Recently, several novel Ras-related GTPases have been iden-
tified that exhibit amino acid sequence features that distin-
guish them from Ras proteins (reviewed in Ref. 8). The Rheb
GTPases are conserved from human to yeast and are subject to
regulated expression in response to a number of stimuli (9, 10).
Although the function of Rheb in mammalian cells is unclear,
the yeast Rheb homologue appears to have the ability to regu-
late cell cycle progression and arginine uptake. The strong
amino acid identity of Rin and Rit proteins with Ras, particu-
larly within their effector domains, suggest that Rit and Rin
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may share partially overlapping functions with Ras (11–13).
Finally, ARHI is an imprinted tumor suppressor gene in breast
and ovarian carcinomas; expression of ARHI in cancer cells
inhibited cell growth and was associated with down-regulation
of cyclin D1 promoter activity and induction of p21WAF1/CIP1
(14). Identification of these atypical family members has ex-
panded our understanding of the roles of Ras-superfamily GTP-
binding proteins in cell physiology and suggests that they are
likely to serve as functionally distinct regulators of as yet to be
characterized signaling cascades.
Here we report the identification of a novel member of the
Ras superfamily of GTP-binding proteins that was discovered
through microarray studies of human breast tumors. Because
it is homologous to Ras and regulated in an estrogen-dependent
manner, we have termed this gene RERG (ras-related and
estrogen-regulated growth inhibitor). RERG has biochemical
properties characteristic of the Ras superfamily, including an
intrinsic ability to bind and hydrolyze GTP; however, overex-
pression of RERG results in a reduced rate of proliferation and
a significant inhibition of both anchorage-dependent and an-
chorage-independent growth.
EXPERIMENTAL PROCEDURES
Microarray Hybridizations and Analysis—All cDNA microarrays
were produced and hybridized as described in Perou et al. (1, 15). For
the MCF-7 estrogen “add back” experiments, the parental vector-only
MCF-7 control cell line (MCF-7-pCDNA3) was grown to 50–70% con-
fluency in RPMI  10% fetal calf serum  penicillin/streptomycin, at
which point the cells were switched to phenol red-free RPMI medium
that contained 10% dextran-charcoal-stripped fetal calf serum (Hy-
clone, Logan, UT) plus penicillin/streptomycin for 48 h. Some of these
estrogen-deprived cells were then cultured in 108 M -17-estradiol
(Sigma) for 4, 8, and 24 h. For the tamoxifen-treated samples, 70%
confluent cultures of MCF-7-pCDNA3 in RPMI  10% fetal calf serum
 penicillin/streptomycin media containing phenol red were treated
with either 1 or 6 M tamoxifen (Sigma) for 48 h. mRNA was prepared
from each sample using a FastTrack 2.0 mRNA kit (Invitrogen) and
compared on 23,000-clone or 44,000-clone cDNA microarrays prepared
at Stanford University (1). In the case of the tamoxifen-treated samples,
the control untreated cells were labeled with Cy3 and compared with
the tamoxifen-treated samples that were labeled with Cy5; for the
estrogen add back experiments, the 48-h estrogen-deprived culture was
labeled with Cy3 and compared with the estrogen-treated samples
(Cy5).
Cell Culture for Transfections—NIH 3T3 mouse fibroblasts were
maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% calf serum. MCF-7 human breast carcinoma cells used in RERG
overexpression studies were maintained in -modified Eagle’s medium
supplemented with 10% fetal calf serum. MCF-7 cells overexpressing
wild type RERG or vector alone (designated MCF-7-Ha-RERG or
MCF-7-pCDNA3) were generated by transfecting cells with either
pCDNA3-Ha-RERG or pCDNA3. Stable MCF-7 transformants were
selected for resistance to 0.5 mg/ml G418, and individual clones were
isolated using cloning rings. All transfections were performed using
LipofectAMINE (Life Technologies, Inc.). Human breast cell lines used
in the Northern blot analyses were obtained from ATCC.
Plasmid Constructions—The complete RERG gene cDNA sequence
was determined (GenBankTM accession number AF339750). The RERG
gene was amplified from IMAGE EST clone 28777 using primers that
contain EcoRI-NdeI and BamHI restriction sites and was subcloned
into the corresponding sites of the yeast expression vector pWHA, which
contains a hemagglutinin (HA) epitope tag, to create pWHA-RERG.
Next, HA-RERG was subcloned into the EcoRI-BamHI sites of the
human expression vector pCDNA3, resulting in pCDNA3-HA-RERG. A
full-length RERG expression construct for recombinant RERG protein
production was generated using polymerase chain reaction to introduce
a BamHI site immediately upstream of the initiator AUG and an XhoI
site directly downstream of the 3 stop codon. The polymerase chain
reaction product was subcloned into the BamHI and XhoI sites of
pET-32a (Novagen) to create pET32a-RERG. Oligonucleotide site-di-
rected mutagenesis was used to generate the single amino acid substi-
tution mutant RERGQ64L (pET32a-RERGQ64L). For localization studies
in live cells, RERG in pKH3 was used as a polymerase chain reaction
template to generate open reading frame cassettes for subcloning into
pEGFP-C3 (CLONTECH). The cassettes contained 5 EcoRI and 3
BamHI restriction enzyme recognition sites and were directionally
cloned downstream of and in-frame with the green fluorescent protein
(GFP) tag of the vector to express GFP-RERG fusion protein.
RNA Isolation and Northern Blot Analysis—To analyze RERG ex-
pression in human breast derived cell lines, RNA was isolated from
various cell lines by acid-phenol extraction as described (16). Total RNA
(25  g) was resolved on 1.3% agarose/formaldehyde gel, denatured,
and transferred to Hybond-N (Amersham Pharmacia Biotech).
[-32P]dCTP-labeled RERG or GAPDH cDNA was prepared with the
random prime kit (Roche Molecular Biochemicals), purified with Seph-
adex G50 NICK column (Amersham Pharmacia Biotech), and hybrid-
ized to the RNA samples using PerfectHyb (Sigma). A similar process
was used to probe a human multiple tissue Northern blot
(CLONTECH).
Recombinant Protein Production and Biochemical Analysis—The re-
combinant plasmid pET32a-RERG was used for the expression of His6-
thioredoxin-RERG fusion protein as described (17). After purification
on nickel nitrilotriacetic acid-Sepharose (Amersham Pharmacia Bio-
tech), RERG protein was exchanged into 50 mM Tris, pH 7.5, 150 mM
NaCl, 10 mM Mg2, 1 mM dithiothreitol, 10% glycerol using a G-25
desalting column (Amersham Pharmacia Biotech) and stored in multi-
ple aliquots at 70 °C. Protein concentrations were determined by the
Bradford assay (Bio-Rad) using bovine serum albumin as a standard.
Recombinant RERG bound 0.12–0.18 mol of nucleotide/mol as meas-
ured by rapid filtration assay (13, 18).
GTP binding to RERG was determined by a nitrocellulose filtration
assay as described previously (18, 19). RERG (1.5 g) or heat-denatured
RERG (95 °C for 5 min) (1.5 g) was incubated in binding buffer (20 mM
Tris pH 7.5, 50 mM NaCl, 0.1% Triton X-100, 1 mM dithiothreitol, 40
g/ml bovine serum albumin, and 2 M GTPS (0.24 Ci/sample))
containing 1 mM EDTA for 1 min at 22 °C, and the free magnesium
concentration was adjusted to 10 mM to initiate nucleotide binding.
After incubation at 22 °C for the indicated times, aliquots were with-
drawn and filtered immediately through BA85 filters (Schleicher and
Schuell), and the amount of bound nucleotide was determined by scin-
tillation counting. Assays to determine the concentration dependence
and specificity of binding and monitor guanine nucleotide dissociation
were performed as described (13, 18).
GTP hydrolysis was quantitated by thin layer chromatography to
resolve GDP and GTP (13, 18). Because the recombinant RERG fusion
protein was found to contain a contaminating phosphatase activity,
unlabeled UTP (2 mM) was added to each reaction as described. GTP
hydrolysis assays were performed in buffer containing 20 mM Tris, pH
7.5, 100 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 2 g of RERG or
RERGQ64L, 10 M [-32P]GTP (0.18 Ci/mmol), and either 4 mM UTP or
2 mM UTP and 2 mM GTP. Reactions were incubated at 22 °C for 1 min
after which the Mg2 concentration was adjusted to 10 mM. The reac-
tions were then incubated at 37 °C for the indicated times, and 1-l
aliquots were removed and analyzed as described. The data were quan-
tified using a STORM 850 PhosphorImager (Molecular Dynamics). The
percentage of GTP hydrolysis was calculated by dividing the amount of
radioactivity in the GDP region by that of the sum of the GTP and GDP
regions.
Western Blot Analysis of Ha-RERG and Biochemical Fractionation—
Total cell lysates were prepared by first growing cells to 80% confluence
on 100-mm plates. Next, the cells were washed one time with 1
phosphate-buffered saline and incubated on ice with 1 ml of radioim-
mune precipitation buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% de-
oxycholate, 0.1% SDS, and 50 mM Tris, pH 7.5) for 30 min with occa-
sional shaking. Cells were then spun for 10 min at 10,000  g, and the
protein concentration of the lysate was determined by the Bradford
assay (Bio-Rad). 40 g of cell lysate was resolved on a 12% SDS-
polyacrylamide gel, and Ha-RERG expression was analyzed by Western
blotting using the anti-HA.11 monoclonal antibody (Berkeley Antibody
Co).
Nuclei of MCF-7-pCDNA3 and MCF-7-Ha-RERG clones 2B6, 1C2,
and 1C4 were isolated from cultures of 80% confluency cells,
trypsinized, washed once with phosphate-buffered saline, and incu-
bated in a 10 pellet volume of prechilled RSB (10 mM NaCl, 1.5 mM
MgCl2, 10 mM Tris-HCl, pH 7.4) on ice for 10 min. Cells were then
Dounce-homogenized on ice. Next, an aliquot of the cell suspension was
examined under a phase contrast microscope for free nuclei. When
greater than 90% of the cell suspension was free nuclei, it was centri-
fuged at 1000  g for 3 min at 4 °C. The supernatant was taken as the
cytosolic fraction, and the pelleted nuclei were resuspended in 10 vol-
umes of RSB. The nuclei were centrifuged and next resuspended in 10
volumes of RSB. Equal fractions of the nuclear fraction and cytosolic
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fraction were loaded onto a 12% SDS-PAGE gel, and Western analysis
was performed.
Localization of GFP-RERG in Cultured Cells—NIH 3T3, MCF-7, or
MDA-MB-231 cells were transiently transfected with 1 g of pEGFP or
pEGFP-RERG using the LipofectAMINE PLUS Reagent (Life Technol-
ogies, Inc.) in serum-free medium according to the manufacturer’s pro-
tocol. Three hours post-transfection, cells were then switched to growth
medium, and 20 h post-transfection, cells were viewed in a Zeiss Axio-
phot fluorescence microscope (63 Plan-APOCHROMAT objective)
equipped with a cooled charge-coupled device (CCD) camera, and digi-
tized images were captured using MetaMorphTM 4.1.4 digital imaging
software (Universal Imaging Corp.). GFP expression was detected from
20 g of cell lysate by immunoblotting with anti-GFP monoclonal an-
tibody (CLONTECH) followed by anti-mouse horseradish peroxidase-
conjugated antibody and visualized by enhanced chemiluminescence
reagent (Pierce).
Anchorage-dependent and Anchorage-independent Growth Assays—
Growth curves were generated for MCF-7 cells expressing wild type
RERG protein or vector controls as described (20). In brief, stable
transfectants were seeded at 2  104 cells/well in 6-well plates, then
trypsinized and counted in triplicate at the indicated times after seed-
ing. Soft agar growth analyses were performed as described previously
(20). Briefly, 104 MCF-7 cells stably expressing empty vector (control) or
RERG overexpressing clones 1C4, 1C2, or 2B6 were seeded in duplicate
into 0.3% Bacto-agar (Difco) over a 0.6% agar bottom layer, with colo-
nies quantitated after 20 days.
Tumorigenicity in Nude Mice—Tumorigenicity analyses were per-
formed as described previously (20), except that 0.72 mg/60-day-time-
release 17--estradiol pellets (Innovative Research of America) were
implanted subcutaneously 24 h before the injection of cells. MCF-7
cells stably expressing empty vector or RERG medium or high express-
ing clones (1C4 and 2B6, respectively) were injected subcutaneously
into 6–8 week athymic nude (BALB/c nu/nu) female mice at 106 cells/
site at two sites per animal (dorsal flanks). Tumor formation was
monitored at least twice a week and measured using calipers over the
skin of the animal from 9–70 days post-injection.
RESULTS
RERG Expression in Primary Breast Tumors—To further
investigate the complex variations in gene expression patterns
seen within primary human breast tumors, a new analytical
method called statistical analysis of microarrays (SAM) (21)
was used to analyze microarray data obtained from 78 different
human breast tumors (2). This analysis resulted in the identi-
fication of 264 genes whose expression correlated with overall
patient survival (see Sørlie et al. (2), Fig. 7 at genome-www.
stanford.edu/breast_cancer/mopo_clinical for the complete 264
clone survival associated cluster diagram). Of particular interest
were genes in which high expression was associated with fa-
vorable patient outcomes and the longest relapse free survival
times. A single cluster of genes, which we refer to as the
“luminal epithelial/ER” cluster, contained most of the genes
whose high expression was associated with long survival times
(2); included within this set of genes was the ER, a known
estrogen-regulated gene (LIV-1), and a novel Ras-like GTPase
that we call RERG for ras-related and estrogen-regulated
growth-inhibitor (Fig. 1A). The mRNA expression pattern of
RERG across these 78 breast tumors was a statistically signif-
icant predictor of patient outcome in a univariate analysis (p 
0.0037); however, as would be expected by its expression pat-
tern, it was not an independent predictor of outcome in a
multivariate analysis because of its correlation with ER expres-
sion (p  0.0001).
The expression pattern of RERG was further investigated in
a series of breast-derived cell lines. Northern blot analysis
detected RERG mRNA in all of the estrogen receptor-positive
breast-derived cell lines (MCF-7, MCF-10A, BT474, and T47D)
but not in any of the ER-negative cell lines examined (SKBR3,
MDA-MB-231, Hs578T, and BT-549 cells) (Fig. 1B).
Nucleotide Sequence and Expression of the RERG Gene—The
RERG gene is encoded by an 2.6-kilobase mRNA that con-
tains a single open reading frame of 600 nucleotides (Gen-
BankTM accession number AF339750). The putative 5 un-
translated region includes an in-frame stop codon 87
nucleotides 5 to the putative translation start site, and the
sequence surrounding the first ATG fits the consensus se-
quence for an efficient translation start site (22). The tissue
distribution of RERG mRNA expression was determined by
Northern blot analysis and screening of dbEST; a 2.6-kilobase
transcript was detected in all 8 tissues examined (heart, brain,
placenta, lung, liver, skin, kidney, and pancreas), with the
highest levels of expression in heart, kidney, and pancreas
(data not shown). A potentially ubiquitous pattern of expres-
sion is supported by Unigene/dbEST expression data
(Hs.21594/hypothetical protein MGC15754/accession Number
BC007997), which indicates that RERG is found in brain, kid-
ney, muscle, prostate, uterus, adrenal gland, aorta, eye, lung,
placenta, stomach, and testis. The RERG gene is located at
12p12, is contained within two overlapping bacterial artificial
chromosome clones (AC007543 and AA022334), and is com-
posed of four exons, the first two of which are separated by a
95-kilobase intron. Analysis of the RERG gene genomic se-
quence identified two potential consensus ER binding sites
within the 5 upstream region (data not shown).
RERG Is an Estrogen-responsive Gene—The location of
RERG within a gene expression cluster that includes the ER,
the high expression of RERG in ER-positive breast cell lines,
and the presence of two potential ER binding sites within the
promoter region suggested that RERG might be an estrogen-
responsive gene. To evaluate this possibility, we used cDNA
microarray analysis and examined RERG expression in re-
sponse to -estradiol stimulation in the estrogen-responsive
MCF-7 cell line (see www4.stanford.edu/MicroArray/SMD for
all microarray primary data files). MCF-7 cells grown in estro-
gen-free media for 2 days were supplemented with -estradiol
(1  108 M) for 4, 8, or 24 h before harvesting mRNA and were
compared with 48-h estrogen-deprived MCF-7 cultures. As
seen in Fig. 1C, RERG was rapidly expressed in response to
-estradiol treatment (1.9-fold stimulation after 4 h and 3-fold
after 24 h), suggesting that it is a direct target of activated ER.
Tamoxifen, an ER antagonist in the breast, acts as an inhibitor
of estrogen-induced responses including the regulation of ER-
responsive genes. Thus, the effect of tamoxifen (6 M) in the
presence of estrogen was examined on global gene expression
patterns. As expected for an ER-regulated gene, RERG expres-
sion was completely repressed by tamoxifen and induced by
estrogen although not as dramatically as other known estro-
gen-regulated genes (see cathepsin D and protein kinase H11
for examples of how known ER-responsive genes behaved in
these experiments) (Fig. 1C).
RERG Is a GTP-binding Protein with Intrinsic GTPase Ac-
tivity—The predicted amino acid sequence of the RERG protein
is encoded by an open reading frame of 600 base pairs that
codes for a 199-amino acid protein that is 50 and 47% identical
to the Dictyostelium Ras-D and Ras-S proteins respectively,
and 44 to 45% identical to human Rit, TC21/R-Ras-2, M-Ras/
R-Ras-3, Rin, and Rap1b (Fig. 2). Although RERG shares sig-
nificant sequence identity and organization with Ras, it also
contains a number of unique features. First, RERG has an
alanine at the position corresponding to the glycine at position
12 of Ki-Ras. Substitution of this residue with alanine results
in the constitutive activation of Ras (23). Another unique feature of
RERG is that it lacks any known COOH-terminal prenylation
motif, indicating that it is not subject to post-translational preny-
lation (24, 25). Prenylation facilitates the association of Ras with
the plasma membrane, and nonprenylated mutants of Ras are
rendered completely inactive. Instead, stretches of basic residues
are found in the RERG COOH-terminal region. These unique
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COOH-terminal features of RERG are similar to those of Rit and
Rin (11–13).
The GTP binding activity of recombinant RERG was assayed
using [35S]GTPS, and bound GTP was separated by rapid
filtration. As seen in Fig. 3A, native recombinant RERG but not
heat-inactivated RERG binds GTPS rapidly in a Mg2-de-
pendent manner upon incubation under standard nucleotide
exchange conditions. As observed with other GTPases, the as-
sociation of guanine nucleotides with RERG was greatly ef-
fected by the concentration of magnesium ions. Replacement of
FIG. 1. mRNA expression of RERG across 78 breast tumors, 3 fibroadenomas, and 4 normal breast samples. A, the RERG gene
(identified in pink) expression pattern is part of the luminal epithelial/ER-positive subset of genes as defined in Sørlie et al. (2). The luminal
epithelial/ER-positive portion of a hierarchical-cluster diagram is shown and was taken from the larger cluster diagram formed when using the 264
cDNA clones that statistically correlated with overall patient survival (see Fig. 7 at //genome-www.stanford.edu/breast_cancer/mopo_clinical for
the complete SAM 264 cluster diagram). The GenBankTM accession numbers next to each gene name represents the accession number for the
actual cDNA clones that were spotted on the microarrays. B, Northern blot analysis of endogenous RERG expression in human breast-derived cell
lines and rat intestinal epithelial cells (RIE-1). C, summary of estrogen modulation microarray experiments. Untreated MCF-7 cells grown in
phenol red-containing media (Cy3) were compared with either 48-h estrogen-deprived cells (Cy5) or 48-h tamoxifen (TAM)-treated cells (Cy5) (left
panel of C). 48-h estrogen-deprived cells (Cy3) were compared with cells that were first deprived of estrogen for 48 h and then stimulated with
estrogen for 4, 8, or 24 h (Cy5) (right panel of C). Selected gene expression results are shown, with the behavior of two known estrogen-regulated
genes (cathepsin D and protein kinase H11 (36, 37)) displayed along with RERG and two other genes (X-box-binding protein 1 and NAT1) that were
also contained within the luminal epithelial/ER-positive expression cluster. The color scale, which represents the fold change observed, for A
(relative to the median expression) and C is present at the lower right. All microarray data can be obtained at genome-www4.stanford.edu/MicroArray/SMD.
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MgCl2 in the reaction with EDTA completely abolished GTPS
binding (data not shown). The binding of both GDP and GTPS
was time- and concentration-dependent (Fig. 3B). The ability of
various nucleotides to compete for [35S]GTPS binding to
RERG was also examined and showed that RERG is a specific
guanine nucleotide-binding protein, since an excess (20-fold) of
unlabeled GTPS, but not CTP, UTP, or ATP, could compete for
[35S]GTPS binding (Fig. 3C). These GTP binding properties
are shared with those of Ras and all other Ras superfamily
GTPases.
The RERG dissociation curves follow a single exponential
pattern, as would be expected for a single class of nucleotide
binding site (Fig. 3D). The half-life for [3H]GDP release from
RERG was extremely slow and, therefore, difficult to assess
accurately in this study (half-life  60 min). Surprisingly,
RERG released GTPS quite rapidly, with a half-life of 7 min.
This rapid rate of release is in contrast to the slower rate of
release seen for the majority of Ras-related proteins.
To determine whether RERG was able to hydrolyze GTP to
GDP, recombinant RERG was incubated with [-32P]GTP, and
the products were analyzed by thin-layer chromatography. As
seen in Fig. 3E, recombinant RERG was capable of hydrolyzing
[-32P]GTP in the presence of an excess of unlabeled UTP.
When UTP was replaced with GTP, we did not observe the
production of GDP, suggesting that the hydrolysis represents
RERG-mediated GTPase activity. Further proof that the
GTPase activity is intrinsic to the RERG protein comes from
analysis of the RERG mutant, RERGQ64L. The analogous mu-
tation in Ras (Q61L) results in a protein with decreased
GTPase activity, and this mutation is found in constitutively
activated and transforming forms of Ras (26). The initial char-
acterization of RERGQ64L found it to have guanine nucleotide
binding properties that were similar to the wild type protein;
however, the GTPase activity of this mutant was greatly re-
duced (Fig. 3E).
Subcellular Localization of RERG—To determine the subcel-
lular localization of RERG, we transiently expressed a GFP-
tagged RERG fusion protein in the MCF-7 and MDA-MB-231
human breast tumor-derived cell lines and in NIH 3T3 mouse
fibroblasts. As shown in Fig. 4A, transient transfection with
the wild type GFP-RERG vector led to the production of an
intact GFP-RERG fusion protein, as determined by anti-GFP
Western blotting. Epifluorescence microscopy of live cells tran-
siently expressing GFP-RERG revealed a uniform and diffuse
distribution throughout the cell cytoplasm, including some sig-
nal in the nucleus (Fig. 4B). A similar expression pattern and
distribution was detected in MCF-7 cells stably expressing
HA-epitope tagged RERG and in a series of additional cell lines
transiently expressing GFP-RERG (data not shown). No cells
were observed that exhibited a plasma membrane localization
of RERG, which is consistent with the lack of a COOH-terminal
prenylation signal sequence. This distribution is similar to that
seen in cells expressing GFP alone (Fig. 4B). The distribution of
HA-tagged RERG was further examined using biochemical
fractionation and Western blot analysis and showed that HA-
RERG was present in the cytosolic fraction of MCF-7 cells that
were stably expressing HA-RERG fusion proteins (Fig. 4C).
RERG Is a Growth Inhibitor in MCF-7 Breast Carcinoma
Cells—The core effector domain of Ras (residues 32–40) is
critical for Ras interactions with Raf and other effector proteins
(4). RERG shares strong, but incomplete, identity with Ras in
this region, suggesting the possibility that RERG may interact
with effectors of Ras (Fig. 2). To address this possibility, we
characterized the potential interaction between RERG and a
panel of known Ras effectors. No interactions between RERG
and Raf, Ral guanine nucleotide dissociation stimulator (Ral-
GDS), phosphoinositide 3-kinase, Rin1, or Rin2 were detected
using a yeast two-hybrid assay (data not shown). Consistent
with the lack of interaction of RERG with Ras effectors, RERG
expression did not result in the appearance of foci of trans-
formed cells when tested in a NIH 3T3 focus-formation assay
(data not shown). Furthermore, unlike what was seen for other
Ras-related proteins that lack COOH-terminal CAAX motifs
(27), no cooperation with activated Raf to cause focus-formation
was seen. Finally, we did not observe any significant inhibitory
effects of wild type or mutant RERG expression on the trans-
formation of NIH 3T3 cells by H-Ras61L (data not shown).
When we closely examined the expression of RERG across
the breast tumors presented in the study by Sørlie et al. (2) and
compared this expression pattern with the expression of the
“proliferation” cluster set of genes (1, 15, 28, 29), we observed
that the tumors that most highly expressed RERG tended to be
the least proliferative and the ones with low to no RERG
expression tended to be the most proliferative (see genome-
www.stanford.edu/breast_cancer/mopo_clinical). The lack of
RERG expression within many breast carcinomas that are
highly proliferative suggests that RERG may function as an
inhibitor of growth. To address this possibility, we generated
MCF-7 cell lines stably overexpressing wild type RERG and
evaluated the consequences on growth in vitro and in vivo. We
chose MCF-7 cells for these analyses because they were posi-
tive for RERG mRNA expression and are an ER-positive cell
line. Clonal populations of MCF-7 cells stably transfected with
an expression vector encoding a HA epitope-tagged version of
FIG. 2. Comparison of the amino
acid sequences of the predicted hu-
man proteins RERG, TC21, Ki-Ras,
Rin, and Dictyostelium Ras-S. The
alignment was performed with the
CLUSTAL W1.6 program (38). Hyphens
represent gaps introduced for optimal
alignment. Numbers are residue num-
bers. Amino acid residues that are identi-
cal in at least four of the five proteins in
the alignment are placed in shaded boxes,
and amino acid similarity is indicated by
boxes. Consensus sequences for GTP bind-
ing regions (G1-G5) (heavy line) and the
position of conserved CAAX motif (dashed
line) are labeled. The position of alanine
15 in RERG is indicated with an asterisk.
h-, human; d, Dictyostelium.
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wild type RERG were generated; empty pCDNA3 vector-trans-
fected cells were also isolated as controls for these analyses.
Western blot studies with anti-HA antibodies verified expres-
sion of HA-RERG in three clonal RERG-overexpressing iso-
lates, with the highest expression seen in 2B6, then 1C4, and
lowest expression in 1C2 (Fig. 5A).
We first assessed the consequences of constitutively high
RERG expression on the rate of proliferation when the cul-
tures were maintained on plastic. All three clonal cell lines
expressing HA-RERG showed reduced rates of cell prolifera-
tion when compared with the vector-transfected control cell
line (Fig. 5B). A similar growth inhibition was observed with
MCF-7 cells when RERG expression was transient-induced
under the control of an inducible promoter (data not shown).
Second, we determined if RERG overexpression affected an-
chorage-independent growth potential of MCF-7 cells. We
determined that MCF-7 cells expressing HA-RERG showed
greatly reduced colony-forming efficiency (50–80% reduc-
tion) in soft agar when compared with the control vector only
MCF-7 cells (Fig. 5C). Finally, we determined if the in vivo
tumorigenic potential of MCF-7 cells was influenced by
RERG overexpression. For these analyses, we inoculated the
cell lines subcutaneously into nude mice and implanted es-
trogen pellets for timed release of estrogen. Tumors grew at
each site injected with empty vector control MCF-7 cells with
a latency of 52 days (Table I). Tumors were also observed in
mice injected with low HA-RERG-expressing 1C4 cells with a
similar latency. In contrast, mice injected with the high HA-
RERG-expressing 2B6 clone remained tumor-free for an ad-
ditional month (Table I).
FIG. 3. Biochemical properties of RERG. A, the time dependence of guanine nucleotide binding to RERG was determined by incubating 1.5
g of RERG (open circle) or heat-denatured RERG (closed circle) with 2 M [35S]GTPS and 1 mM EDTA for 1 min. The free Mg2 was then adjusted
to 10 mM to initiate GTPS binding. At the indicated times, the amount of [35S]GTPS bound was determined by rapid filtration and scintillation
counting. B, the concentration dependence of guanine nucleotide binding to RERG was determined by incubating EDTA-treated RERG (1.5 g)
with the indicated concentration of either [3H]GDP (closed circle) or [35S]GTPS (open circle). Free Mg2 was adjusted to 10 mM, and radiolabeled
nucleotide binding was determined by rapid filtration. C, the specificity of RERG guanine nucleotide binding was determined by incubating RERG
(1.5 g) with 2 M [35S]GTPS (Control) or 2 M [35S]GTPS and 40 M indicated non-radiolabeled ribonucleotide with 1 mM EDTA for 1 min. Free
Mg2 was then adjusted to 10 mM, and the bound [35S]GTPS at 10 min was determined by rapid filtration. The amount of radionucleotide bound
in the absence of non-radiolabeled ribonucleotide was set as 100%. D, the guanine nucleotide dissociation rates from RERG were determined by
incubating RERG (1.5 g) with either 2 M [3H]GDP (open circle) or [35S]GTPS (closed circle) and 1 mM EDTA for 1 min. The free Mg2 was then
adjusted to 10 mM to initiate binding. To initiate dissociation, a 100-fold molar excess of unlabeled GDP or GTPS was added, and the exchange
of radiolabeled nucleotide was measured as described under “Experimental Procedures.” The amount bound at 0 min was set to 100%. E, the ability
of RERG and RERGQ64L to hydrolyze GTP was determined as described under “Experimental Procedures.” RERG (squares) and RERGQ64L (circles)
(2 g) were incubated with [-32P]GTP (10 M; 2 Ci/mmol) and 1 mM EDTA in the presence of either 4 mM UTP (open symbols) or 2 mM UTP and
2 mM GTP (closed symbols) for 1 min. The free Mg2 was then adjusted to 10 mM to initiate binding, and 1-l aliquots were removed and analyzed
by thin layer chromatography. All values are the average of duplicate points and are representative of experiments repeated at least three times.
WT, wild type.
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DISCUSSION
We employed microarray analyses to identify genes whose
expression correlated with a favorable prognosis for breast
cancer patients. One gene identified represents a novel ras-
related gene that we have designated RERG (ras-related and
estrogen-regulated growth inhibitor). We determined that
RERG expression was decreased or lost in a significant per-
centage of primary human breast tumors that showed a poor
clinical prognosis and was regulated by estrogen stimulation in
vitro. Like Ras, RERG protein can bind and hydrolyze GTP,
indicating that RERG also functions as a GTPase. Unlike Ras,
RERG lacks any known COOH-terminal prenylation signal
sequence and exhibited a cytosolic rather than plasma mem-
brane subcellular location. RERG did not interact with effec-
tors of Ras, indicating that RERG function is likely distinct
from that of Ras. Finally, in contrast to the growth-promoting
activity associated with Ras and other Ras-related proteins,
RERG overexpression inhibited the growth of breast tumor
cells in vitro and in vivo. When taken together, these observa-
tions support an important role for the loss of RERG function in
the development of breast cancer.
We have identified a novel estrogen-regulated member of the
Ras superfamily of small GTP-binding proteins. Analysis of the
RERG cDNA sequence indicates that it encodes a protein of 199
amino acids with a deduced molecular mass of 22,607 Da. The
regions with highest homology between RERG and other Ras
family members corresponds to the five regions of Ras involved
in GTP binding (G1-G5) (Fig. 2) (30). The core consensus se-
quence of the G1 region, GX4GK(S/T) (Ras residues 10–17) is
present in RERG; however, RERG contains an alanine at the
position corresponding to glycine 12 of Ras and the majority of
Ras superfamily proteins. Interestingly, ARHI/NOEY2 also
harbors a naturally occurring “activating” substitution at this
position. A G12A substitution in Ras causes an impairment of
intrinsic GTPase activity and results in a constitutively acti-
vated and transforming Ras protein (23). We found, however,
that RERG possesses an intrinsic GTPase activity that was
impaired when a mutation analogous to the RasQ61L mutation,
which abolishes the intrinsic and GTPase-activating protein-
stimulated GTPase activity of Ras and other Ras family
GTPases, was introduced into RERG. Thus, despite this struc-
tural difference from Ras, it is possible that RERG is not consti-
tutively active and GTP-bound. It will be important to determine
whether there are specific guanine nucleotide exchange factors
and/or GTPase-activating protein that regulate RERG function
and if RERG-GTP levels are regulated by extracellular stimulus-
mediated signaling pathways.
Although RERG shares strong sequence identity with the
core effector domain of Ras, we determined that RERG did not
bind to Raf and other effectors of Ras. This observation to-
gether with the lack of transforming activity in NIH 3T3 cells
argues that RERG function is mediated by interactions with
downstream targets distinct from those of Ras. Although many
Ras superfamily GTPases have been described as positive reg-
ulators of cell growth and differentiation (8), others including
Rap1 and ARH1 have been implicated as negative regulators of
Ras-mediated pathways (14, 31). Our studies suggest that
RERG functions as a negative growth regulator without di-
rectly affecting Ras signaling. Defining RERG-mediated signal-
ing cascades will require further investigation.
FIG. 4. Subcellular distribution of
RERG in living cells. A, Western blot
analysis of MCF-7, MDA-MB-231, and
NIH 3T3 cells using an anti-GFP mono-
clonal antibody (CLONTECH) shows that
GFP-RERG is expressed at the predicted
molecular weight for the fusion protein.
B, RERG is expressed in the cytoplasm
and nucleus of MCF-7, MDA-MB-231, and
NIH 3T3 cells when ectopically expressed.
The cell lines were transiently trans-
fected with DNA constructs encoding un-
fused GFP (top panels) or GFP-RERG
(bottom panels), and the live cells were
examined by epifluorescence microscopy
as described under “Experimental Proce-
dures.” C, biochemical fractionation of
MCF-7 cell clones that stably express Ha-
RERG into nuclear (N) and cytoplasmic
(C) fractions shows that HA-RERG is pre-
dominately located in the cytoplasmic
fraction.
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Most Ras-related proteins are membrane-associated and
specific membrane localization is both essential and central to
their biological activity (25, 32). Membrane binding generally
requires the post-translational addition of a COOH-terminal
isoprenyl group by a mechanism that involves the prenyltrans-
ferase recognition of conserved cysteine motifs (prenylation) as
well as other CAAX-signaled posttranslational modifications
(24). One of the distinguishing structural features of RERG is
a unique COOH-terminal sequence that contains stretches of
basic residues but lacks a consensus motif for lipid modification
(Fig. 2). Indeed, epifluorescence microscopy revealed that
RERG is predominately localized in the cytoplasm when ex-
pressed in a variety of cell types including breast derived cell
lines (Fig. 4). In this regard, RERG is similar to the recently
described Rem/Rad/Gem/Kir proteins, which lack a COOH-
terminal CAAX motif and appear to be localized to the cytosol
(18, 33). Additional studies including the localization of endog-
enous RERG protein and studies to identify RERG-interacting
proteins, will be necessary before the significance of this unique
cellular distribution can be fully understood.
An important finding of this study is that the expression of
RERG in MCF-7 breast carcinoma cells can be modulated by
estrogen and anti-estrogen treatment (Fig. 1C). Estradiol stim-
ulation markedly and rapidly increased the expression of
RERG in a time-dependent manner, whereas tamoxifen or
estrogen deprivation potently repressed RERG expression to no
expression. Because two consensus estrogen response elements
were found within the promoter region of the RERG gene, we
believe RERG to be an estrogen-regulated gene. Consistent
with this hypothesis is our finding that RERG expression dem-
onstrated a high degree of correlation with ER in both breast
tissue-derived cell lines and primary tumors (Fig. 1, A and B).
The expression of the estrogen receptor has important impli-
cations for the biology of breast carcinomas. Patients with
tumors that express ER have a longer disease-free interval and
overall survival than those patients with tumors that lack ER
expression (34, 35). The marked physiological and phenotypic
differences between ER-positive and ER-negative breast tu-
FIG. 5. Inhibition of anchorage-de-
pendent and anchorage-independent
growth of MCF-7 cells by the expres-
sion of RERG. A, cytosolic extracts (40
g of protein) from MCF-7 cells stably
expressing empty vector or Ha-RERG
overexpressing clones 1C2, 1C4, or 2B6
were subjected to Western blot analysis
using an anti-HA monoclonal antibody. B,
growth curves for MCF-7 cells stably ex-
pressing empty vector or Ha-RERG clones
were generated as described under “Ex-
perimental Procedures.” Cells were
counted from triplicate wells every day for
7 days. Data shown are representative of
three independent experiments. C,
MCF-7 clones stably expressing empty
vector or Ha-RERG isolates 1C4, 1C2, or
2B6 were seeded in duplicate into 0.3%
soft agar over a 0.6% agar bottom layer
and maintained at 37 °C. Colonies were
quantitated after 20 days. Data shown
are expressed as a percent of colonies
formed by control vector-transfected cells
and are an average of three independent
experiments.
TABLE I
Suppression of MCF-7 cell tumor formation in nude mice by Rerg
expression
6–8 week old athymic (nude) mice implanted with estrogen pellets
were injected with MCF-7 cells stably expressing empty vector or Rerg-
overexpressing clones 1C4 or 2B6. Tumor formation was monitored
approximately twice a week from 9–70 days post-injection.
Day post-injection Vector Rerg 1C4 Rerg 2B6
9 0/4 0/4 0/4
17 0/4 0/4 0/4
22 0/4 0/4 0/4
31 0/4 0/3 0/4
37 0/4 0/3 0/4
43 0/4 1/3 0/4
47 0/4 1/3 0/4
52 2/4 1/3 0/4
57 2/4 2/3 0/4
65 2/4 2/3 0/4
70 2/4 2/3 0/4
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mors have been hypothesized to be due to differences in gene
expression between these two tumor types. Therefore, there is
a great need to identify estrogen-responsive genes within pri-
mary breast tumors and define their role in tumorigenesis.
These studies indicate that RERG may be of biological and/or
clinical importance in breast cancer and suggest an important
role for RERG in the physiological response of breast epithelial
cells to estrogen.
The role of RERG in breast tumor growth was evaluated in
several experimental models. The overexpression of RERG in
MCF-7 cells markedly inhibited their anchorage-dependent
growth rates under standard tissue culture conditions (Fig.
5B). More importantly, elevated RERG expression significantly
reduced colony formation in soft agar (Fig. 5C) and inhibited
tumor formation in nude mice (Table I). Taken together, these
results suggest that loss of RERG expression may facilitate
transformation of breast luminal cells. It should be noted that
the phenotypes caused by overexpression of RERG in MCF-7
cells are entirely consistent with its expression pattern seen
across the set of 78 breast tumors presented in Fig. 1; the group
of tumors that most highly expressed the luminal epithelial/
ER-positive set of genes (that contains RERG and termed “lu-
minal subtype A”), were on average some of the least prolifer-
ative tumors (1, 2). These studies suggest that RERG may
function as a negative growth regulator in breast epithelial
cells. Whether this inhibition depends on the cellular context in
which RERG is expressed and the identification of the signal
transduction cascades that are impacted remains to be
determined.
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